Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyell Immunopharma, Inc.

0.4636
-0.0116-2.44%
Volume:461.18K
Turnover:210.15K
Market Cap:136.92M
PE:-0.35
High:0.5100
Open:0.4925
Low:0.4456
Close:0.4752
Loading ...

Lyell Immunopharma Announces Oral Presentation of New Clinical Data From the Phase 1/2 Trial of Lyl314 for the Treatment of Large B-Cell Lymphoma at the International Conference on Malignant Lymphoma (Icml) 2025

THOMSON REUTERS
·
Yesterday

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

GlobeNewswire
·
Yesterday

Cautious Hold Rating on Lyell Immunopharma Amid Promising Developments and Competitive Challenges

TIPRANKS
·
16 Apr

Lyell Immunopharma Says its Relapsed Large B-Cell Lymphoma Therapy Receives US FDA's REMAT Designation

MT Newswires Live
·
15 Apr

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (Rmat) Designation for Lyl314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

THOMSON REUTERS
·
15 Apr

Director’s Bold Move: Major Stock Purchase in Lyell Immunopharma!

TIPRANKS
·
03 Apr

Lyell Immunopharma to Cut Jobs, Close West Hills Plant

Dow Jones
·
02 Apr

BRIEF-Lyell Immunopharma Inc - To Close West Hills Manufacturing Facility - SEC Filing

Reuters
·
02 Apr

Lyell Immunopharma Inc - to Close West Hills Manufacturing Facility - SEC Filing

THOMSON REUTERS
·
02 Apr

Lyell Immunopharma Inc: Reiterates Its Financial Guidance

THOMSON REUTERS
·
02 Apr

Investor Interest in Lyell Immunopharma Stock (LYEL) Surges on Positive Analyst Report

TIPRANKS
·
23 Mar

Favourable Signals For Lyell Immunopharma: Numerous Insiders Acquired Stock

Simply Wall St.
·
20 Mar

Lyell Immunopharma Price Target Maintained With a $1.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

Lyell Immunopharma’s Global Expansion Strategy: Navigating Risks and Challenges

TIPRANKS
·
13 Mar

Lyell Immunopharma Q4 Sales $11.00K Down From $13.00K YoY

Benzinga
·
12 Mar

BRIEF-Lyell Immunopharma Q4 Net Income USD -191.935 Million

Reuters
·
12 Mar

Lyell Immunopharma Q4 Revenue USD 11 Thousand

THOMSON REUTERS
·
12 Mar

Lyell Immunopharma Q4 Operating Expenses USD 201.158 Million

THOMSON REUTERS
·
12 Mar

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

GlobeNewswire
·
19 Feb

Following a 67% decline over last year, recent gains may please Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners

Simply Wall St.
·
17 Feb